Antidepressant Medications: A Clinical Review Across Generations

1. A Brief History of Antidepressants

The history of antidepressants is largely a story of serendipity subsequently rationalized into mechanistic frameworks. Each generation of agents has expanded the clinician's armamentarium while simultaneously illuminating the limits of prior therapies and the incompleteness of monoamine-centric theories of depression.

2. Classes, Mechanisms, and Key Pharmacology

Monoamine Oxidase Inhibitors (MAOIs)

MAOIs inhibit monoamine oxidase enzymes (MAO-A and MAO-B), which catabolize serotonin, norepinephrine, dopamine, and dietary amines. Irreversible, non-selective MAOIs (phenelzine, tranylcypromine, isocarboxazid) block both isoforms permanently; enzyme regeneration requires 2–3 weeks after discontinuation. Selegiline (selective MAO-B at low doses, non-selective at antidepressant doses) is available as a transdermal patch with reduced dietary restrictions.

Moclobemide, a reversible inhibitor of MAO-A (RIMA) widely used outside the United States, has a more favorable tyramine safety profile because dietary tyramine can competitively displace it from the enzyme. Its absence from the US market reflects regulatory and commercial factors rather than clinical inferiority.

The tyramine restriction is mandatory with irreversible MAOIs: dietary tyramine, normally catabolized by intestinal and hepatic MAO, reaches the systemic circulation and triggers norepinephrine release from sympathetic terminals, causing potentially life-threatening hypertensive crises. Foods to avoid include aged cheeses, cured meats, fermented products, tap beer, and tyramine-containing supplements.

Tricyclic Antidepressants (TCAs)

TCAs inhibit both the serotonin transporter (SERT) and norepinephrine transporter (NET), with variable selectivity. Clomipramine is most serotonergic; desipramine and nortriptyline are most noradrenergic. Their clinical liabilities derive from off-target actions: anticholinergic (muscarinic M1 blockade), antihistaminic (H1 blockade causing sedation and weight gain), and alpha-1 adrenergic blockade (orthostatic hypotension). Critically, TCAs block cardiac fast sodium channels, prolonging the QRS complex and QTc interval. This makes them acutely lethal in overdose — as few as 10-times the therapeutic dose can cause fatal arrhythmia — a critical consideration when prescribing in patients with suicidal ideation.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs share the common mechanism of SERT blockade with high selectivity, producing a class effect on MDD with individual differences in pharmacokinetics, CYP450 inhibition, and secondary receptor effects. Fluoxetine's long half-life (1–4 days for parent compound; 4–16 days for active metabolite norfluoxetine) provides natural protection against discontinuation syndrome and permits flexible dosing. Paroxetine has the shortest half-life among SSRIs and the highest anticholinergic activity of the class, as well as potent CYP2D6 inhibition. Fluvoxamine is a particularly potent CYP1A2 and CYP3A4 inhibitor, yielding significant drug interaction potential.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Venlafaxine and duloxetine inhibit both SERT and NET, with noradrenergic effects becoming dose-dependent: serotonergic predominance at low doses shifting toward greater NE contribution at higher doses. This noradrenergic activity underlies both the analgesic properties of duloxetine (FDA-approved for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain) and dose-related hypertension and urinary hesitancy. Desvenlafaxine, the O-desmethyl metabolite of venlafaxine, bypasses hepatic CYP2D6 metabolism, offering a more predictable concentration independent of metabolizer status.

Norepinephrine-Dopamine Reuptake Inhibitor (NDRI): Bupropion

Bupropion is mechanistically distinct: it inhibits NET and DAT with minimal serotonergic activity. This profile explains both its unique advantages (absence of sexual dysfunction, weight neutrality to weight loss, activating properties useful in atypical and hypersomnic depression) and its adverse effects (activation, insomnia, dose-dependent seizure risk). Bupropion is contraindicated in patients with seizure disorders, bulimia nervosa, or anorexia nervosa (where electrolyte disturbances lower seizure threshold), and in patients undergoing abrupt alcohol or benzodiazepine withdrawal.

Noradrenergic and Specific Serotonergic Antidepressant (NaSSA): Mirtazapine

Mirtazapine acts through alpha-2 adrenergic antagonism (disinhibiting norepinephrine and serotonin release) and blockade of 5-HT2A, 5-HT2C, and 5-HT3 receptors, along with potent H1 antagonism. The 5-HT2 and 5-HT3 blockade attenuates nausea and sexual dysfunction relative to SSRIs, while H1 blockade causes pronounced sedation (more so at lower doses) and weight gain. Its rapid onset of sedation makes it clinically useful in MDD with insomnia, agitation, or poor appetite.

Multimodal Agents: Vortioxetine and Vilazodone

Vortioxetine inhibits SERT while acting as an agonist at 5-HT1A, partial agonist at 5-HT1B, and antagonist at 5-HT1D, 5-HT3, and 5-HT7 receptors. Meta-analytic data suggest possible advantages in cognitive domains (processing speed, executive function) potentially mediated by 5-HT3 antagonism and downstream modulation of glutamate and acetylcholine. Its sexual dysfunction burden appears lower than SSRIs. Vilazodone combines SSRI activity with 5-HT1A partial agonism, theoretically providing anxiolytic augmentation; its clinical differentiation from standard SSRIs is modest in practice.

Novel Mechanisms: Esketamine, Zuranolone, and Brexanolone

Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects via NMDA receptor antagonism, with downstream synaptogenesis mediated through BDNF-TrkB signaling and mTOR pathway activation. Because it has dissociative and abuse potential, it is available only through a REMS program as intranasal administration in certified healthcare settings. It is approved for treatment-resistant depression and MDD with acute suicidal ideation or behavior (MDSI), representing the first antidepressant approved for suicidality.

Brexanolone (IV) and zuranolone (oral) are synthetic analogues of allopregnanolone, a progesterone metabolite that acts as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors. Their mechanism is entirely distinct from monoamine-based antidepressants. Brexanolone is a 60-hour intravenous infusion for postpartum depression administered in a certified healthcare facility. Zuranolone is a 14-day oral course approved for both MDD and postpartum depression, with a rapid onset (as early as day 3).

3. Evolving Indications

The therapeutic footprint of antidepressants has expanded dramatically beyond MDD. SSRIs and SNRIs are now first-line treatments for multiple anxiety and stress-related disorders, with efficacy supported by extensive randomized controlled trial data and meta-analyses. This expansion has practical clinical implications: many patients presenting to primary care or psychiatry with "depression" have comorbid anxiety disorders that may drive the choice of agent.

Anxiety and Related Disorders

SSRIs and SNRIs are first-line pharmacotherapy for generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and obsessive-compulsive disorder (OCD). In OCD, doses are typically higher than for MDD (e.g., fluoxetine 60–80 mg, sertraline 200 mg), and response is often slower (8–12 weeks to full assessment). Bupropion is relatively contraindicated in anxiety given its activating, dopaminergic properties.

PTSD

Sertraline and paroxetine are the only FDA-approved antidepressants for PTSD. Venlafaxine has substantial off-label evidence. The VA/DoD Clinical Practice Guidelines rate both pharmacotherapy and trauma-focused psychotherapy (CPT, PE, EMDR) as first-line. Pharmacotherapy is typically adjunctive rather than curative in PTSD, with 20–30% symptom reduction achievable across domains.

Pain Syndromes

The noradrenergic pathway modulates spinal nociceptive transmission via descending inhibitory circuits. Duloxetine is FDA-approved for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. TCAs remain effective for neuropathic pain and migraine prophylaxis at doses below those needed for MDD, and their tolerability in this context may be more acceptable when framed as analgesia.

4. Side Effects Across Generations — Evolution and Shortcomings

Each successive generation of antidepressants has improved upon the safety profile of its predecessors while introducing new, often class-specific liabilities. Understanding these profiles at a mechanistic level allows for anticipatory counseling and rational drug selection.

MAOIs

Irreversible MAOI use requires strict dietary adherence to avoid tyramine-induced hypertensive crises (presenting as sudden severe headache, diaphoresis, tachycardia, and potentially intracranial hemorrhage). Drug interactions are extensive and potentially fatal: concurrent serotonergic agents risk serotonin syndrome; sympathomimetics risk hypertensive crisis. Other effects include orthostatic hypotension, insomnia, weight gain, and sexual dysfunction. These agents should be reserved for treatment-resistant or atypical depression under specialist supervision with clear dietary and drug interaction counseling documented.

TCAs

Anticholinergic effects are often dose-limiting: dry mouth, constipation, urinary retention, blurred vision, and cognitive impairment (particularly problematic in elderly patients). Antihistaminic activity causes significant sedation and weight gain. Orthostatic hypotension from alpha-1 blockade increases fall risk, especially in older adults. QTc prolongation requires ECG monitoring at higher doses. The narrow therapeutic index and lethality in overdose (QRS widening, ventricular arrhythmia) makes prescribing in at-risk patients a critical safety concern.

SSRIs

Sexual dysfunction (30–40% incidence) is the most clinically significant SSRI adverse effect affecting long-term adherence — encompassing decreased libido, delayed orgasm, and anorgasmia in both sexes, as well as erectile dysfunction. GI effects (nausea, diarrhea) are common at initiation and often transient. Hyponatremia from SIADH, mediated by serotonin-induced ADH secretion, is clinically significant in elderly patients and should be screened at initiation and monitored periodically. Antiplatelet activity from SERT inhibition in platelets increases bleeding risk, particularly GI bleeding with concurrent NSAIDs or anticoagulants. Discontinuation syndrome (see Section 6) is a meaningful concern with short-half-life agents. There is a small but measurable increase in suicidal ideation in patients under age 25 (black box warning; see Section 6).

SNRIs

SNRIs share the SSRI side effect profile and add noradrenergic effects: dose-dependent hypertension (particularly venlafaxine at doses above 150 mg/day), diaphoresis, urinary hesitancy, and increased heart rate. Discontinuation syndrome is especially prominent with venlafaxine due to its short half-life. Blood pressure monitoring is warranted in all patients initiated on SNRIs.

Bupropion

Activation, insomnia, dry mouth, and headache are common at initiation. The dose-dependent seizure risk (approximately 0.4% at standard doses, 4% at high doses previously used) is manageable with appropriate dose limits: do not exceed 450 mg/day total, 150 mg per immediate-release dose. Contraindications include seizure disorders, bulimia nervosa, anorexia nervosa, and acute alcohol withdrawal. No clinically significant sexual dysfunction or weight gain.

Mirtazapine

Sedation is universal and greatest at lower doses (7.5–15 mg) due to proportionally greater H1 antagonism relative to alpha-2 effects at low doses — counterintuitively, higher doses may be less sedating. Weight gain and metabolic effects are substantial; long-term use warrants metabolic monitoring. The discontinuation syndrome is notably mild due to its prolonged half-life and non-SERT mechanism.

Vortioxetine

Nausea is the most common adverse effect, particularly at initiation. Sexual dysfunction is present but lower in incidence than SSRIs, consistent with the 5-HT3 antagonism reducing some serotonergic effects. It does not cause significant weight gain, sedation, or QTc prolongation.

Side Effect Heatmap: Major Antidepressants

Relative burden by drug class across six clinically relevant adverse effect domains. Green = low, yellow = moderate, orange = high, red = very high.

5. Choosing the Right Antidepressant

The landmark Cipriani et al. network meta-analysis (Lancet, 2018) synthesized 522 trials enrolling over 116,000 participants and found that all antidepressants were more effective than placebo for MDD. Escitalopram and sertraline consistently ranked highest for the combination of efficacy and acceptability. However, no single agent is universally optimal; drug selection requires individualization based on clinical profile, comorbidities, prior medication history, and patient preferences.

Clinical Decision Framework

Antidepressant Selection: Decision Flowchart

Simplified clinical decision algorithm for initial antidepressant selection in MDD.

6. Discontinuation Syndrome and Special Concerns

Discontinuation Syndrome: FINISH Mnemonic

Antidepressant discontinuation syndrome arises from abrupt or rapid cessation of serotonergic (and noradrenergic) agents. It is not pharmacological addiction but rather a physiological rebound from the abrupt reversal of receptor adaptations that developed during treatment. Recognition is clinically important to distinguish from depression relapse or viral illness.

Risk Stratification by Drug

• Highest risk: Paroxetine (short half-life, potent anticholinergic rebound, autoinhibition); venlafaxine (half-life 5 hours; "brain zaps" particularly prominent)
• Moderate risk: Sertraline, escitalopram, duloxetine, desvenlafaxine
• Low risk: Fluoxetine (acts as its own taper via norfluoxetine half-life of 4–16 days)
• Minimal risk: Mirtazapine, bupropion (different mechanism, SERT not primarily involved)

Management strategies include: planned gradual taper over weeks to months (longer courses warrant longer tapers), switching to fluoxetine as a "bridge" drug exploiting its long half-life, and symptomatic management of individual symptoms (antihistamines for dizziness, low-dose benzodiazepines short-term for severe anxiety).

Black Box Warning: Suicidality in Patients Under Age 25

In 2004, the FDA required a black box warning for antidepressants regarding increased risk of suicidal ideation and behavior in pediatric patients with MDD; this was extended to adults under 25 in 2006. The evidence base derives from pooled data showing a small but statistically significant increase in suicidal ideation (not completed suicides) in the first weeks of treatment, particularly in the under-18 population.

Clinical context is critical: untreated depression carries far greater suicide risk than treated depression. The warning should prompt close follow-up (weekly for the first month in younger patients), not avoidance of pharmacotherapy. Monitoring should focus on worsening anxiety, agitation, activation, and emergence of suicidal ideation during the first 4 weeks.

Serotonin Syndrome

Serotonin syndrome results from excess serotonergic neurotransmission, typically from drug combinations: SSRI/SNRI + MAOI (most dangerous; avoid combination; mandatory 14-day washout from SSRI before MAOI, 5-week washout from fluoxetine), SSRI + tramadol/fentanyl/opioids with serotonergic activity, linezolid (MAO inhibitor), triptans, or dextromethorphan.

The Hunter Serotonin Toxicity Criteria identify serotonin syndrome by the presence of clonus (spontaneous, inducible, or ocular), agitation, diaphoresis, tremor, and hyperreflexia. Severe cases involve hyperthermia, rhabdomyolysis, and DIC. Management: discontinue the offending agent, supportive care, cyproheptadine (5-HT2A antagonist) for mild-moderate cases, benzodiazepines for agitation and muscle rigidity, and ICU admission for severe hyperthermia.

7. Routine Monitoring

Systematic monitoring transforms antidepressant prescribing from transactional to longitudinal care. Structured assessment of response and tolerability allows for timely dose optimization and early identification of adverse effects.

Duration of Treatment

Treatment duration recommendations are based on recurrence risk:

• First episode, full remission: Continue for 6–9 months following remission before considering discontinuation
• Second episode: Continue for at least 1–2 years
• Third or more episodes, or high-risk features (severe, prolonged, early onset, psychotic): Indefinite maintenance therapy, reassessing annually
• The risk of relapse upon discontinuation is approximately 50% in the first year following cessation after a first episode; this increases with each subsequent episode

Drug-Specific Monitoring Notes

• SSRIs/SNRIs in elderly: Monitor serum sodium at baseline and 2–4 weeks after initiation; SIADH-mediated hyponatremia is underrecognized
• SNRIs: Blood pressure at baseline and with dose changes; relevant at doses above venlafaxine 150 mg/day
• Bupropion: No routine labs; ensure dose limits respected; monitor for activation and sleep disturbance
• Lithium augmentation: Lithium levels, renal function (creatinine, eGFR), TSH at baseline and every 3–6 months
• MAOI: Blood pressure at baseline; dietary counseling documentation; full medication reconciliation; patient education card
• Esketamine: REMS-mandated monitoring for 2 hours post-dose for dissociation, sedation, and blood pressure; administered in certified healthcare settings only